Next Article in Journal
Diabetogenic Effects of Ochratoxin A in Female Rats
Next Article in Special Issue
The Uremic Toxin Indoxyl Sulfate Accelerates Thrombotic Response after Vascular Injury in Animal Models
Previous Article in Journal
Modification of the Mycotoxin Deoxynivalenol Using Microorganisms Isolated from Environmental Samples
Previous Article in Special Issue
Inflammatory Cytokines as Uremic Toxins: “Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son”
Article Menu
Issue 4 (April) cover image

Export Article

Comment of Toxins 2016, 8(12), 358.

Open AccessComment
Toxins 2017, 9(4), 142; doi:10.3390/toxins9040142

Comment on Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. Toxins 2016, 8, 358

Division of Nephrology, Department of Internal Medicine, Federal University of Paraná, 80060-900 Curitiba, Brazil
Experimental Nephrology Laboratory, Basic Pathology Department, Federal University of Paraná, 81531-980 Curitiba, Brazil
Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt, Paris 92104, France
INSERM Unit 1018, CESP, University of Versailles-Saint-Quentin-en-Yvelines, University Paris-Saclay, 54500 Villejuif, France
Author to whom correspondence should be addressed.
Academic Editor: Raymond Vanholder
Received: 19 March 2017 / Revised: 19 March 2017 / Accepted: 11 April 2017 / Published: 17 April 2017
(This article belongs to the Special Issue Novel Issues in Uremic Toxicity)
View Full-Text   |   Download PDF [201 KB, uploaded 17 April 2017]


Recently, the clinical and experimental evidences that support the toxic effects of indoxyl sulfate, a protein-bound uremic toxin in chronic kidney disease (CKD) patients, has been discussed. In this panorama, the authors described several in vitro and in vivo studies, suggesting that indoxyl sulfate may play a part in the pathogenesis of low turnover bone disease. However, the discussion claims the need for relevant clinical studies in CKD patients whose bone turnover biomarkers and bone histomorphometry were assessed in order to demonstrate the association between serum levels of indoxyl sulfate and bone turnover. We would like to underline the availability of this clinical data to support the concept that indoxyl sulfate may play a part in the pathogenesis of low turnover bone disease in CKD patients. View Full-Text
Keywords: uremic toxin; indoxyl sulfate; bone disease uremic toxin; indoxyl sulfate; bone disease
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Barreto, F.C.; Barreto, D.V.; Stinghen, A.E.M.; Massy, Z.A. Comment on Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies. Toxins 2016, 8, 358. Toxins 2017, 9, 142.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top